62009-47-6Relevant academic research and scientific papers
PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
-
Paragraph 0182; 0183, (2021/03/05)
Provided herein are compounds of formula (I) as shown below, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
-
Page/Page column 100, (2021/11/20)
Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I).
PERK INHIBITING INDOLINYL COMPOUNDS
-
Paragraph 0171; 0172, (2021/03/05)
Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders, wherein Q is selected from (Ia), (Ib) ou (Ic).
Scalable synthesis of favipiravir: Via conventional and continuous flow chemistry
Charoensetakul, Netnapa,Khamkhenshorngphanuch, Thitiphong,Srikun, Onsiri,Srimongkolpithak, Nitipol,Thongpanchang, Chawanee,Tiyasakulchai, Thanat,Yuthavong, Yongyuth
, p. 38691 - 38693 (2021/12/20)
Decagram scale synthesis of favipiravir was performed in 9 steps using diethyl malonate as cheap starting material. Hydrogenation and bromination steps were achieved by employing a continuous flow reactor. The synthetic process provided a total of 16% yield and it is suitable for larger-scale synthesis and production. This journal is
BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
-
Paragraph 00680, (2018/08/20)
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
Synthetic method of 2-aminomalononitrile
-
Paragraph 0016; 0017; 0018; 0019, (2018/07/30)
The invention discloses a synthetic method of 2-aminomalononitrile. The synthetic method comprises the following steps of: 1) adopting aminomalonic acid diethyl ester as a starting material, directlyplacing into 40-60w/v% of ammonium-chloride aqueous solution, reacting for 2-5 hours at a temperature of 100-120 DEG C and preparing to obtain 2-aminopropanediamide; 2) dissolving 2-aminopropanediamide prepared in the step 1) into an organic solvent, heating to rise the temperature, adding solid phosgene, heating and refluxing for 10-12 hours to generate 2-aminomalononitrile. The synthetic methoddisclosed by the invention is simple, pollution-free, safe and environmentally friendly and provides basis for further application of 2-aminomalononitrile.
Synthesis and antiviral evaluation of the 2'-c-methyl branched derivative of a nucleoside analog inhibitor of RNA viral infections, T-1106
Pierra, Claire,Counor, Clement,Storer, Richard,Gosselin, Gilles
experimental part, p. 1327 - 1333 (2012/04/17)
An example of a 2'-C-methyl branched nucleoside analogue bearing 3,4-dihydro-3-oxopyrazine-2-carboxamide as the base, namely 4-(2-C-methyl- β-D-ribofuranosyl)-3-oxo-3,4-dihydropyrazine-2-carboxamide, is reported. This compound was synthesized following a Vorbrueggen's glycosylation procedure in a few steps. When evaluated in cell culture experiments against a broad range of viruses, this compound did not exhibit any significant antiviral effect or cytotoxicity.
SULFONIC ACID SALT COMPOUND OF 4-CARBAMOYL-5-HYDROXY-IMIDAZOLE DERIVATIVE
-
Page/Page column 5; 6, (2010/07/03)
The object is to provide a stable SM-108 derivative, which is effective as a carcinostatic agent, particularly an SM-108 derivative having good storage stability. An SM-108 compound having good storage stability can be produced by producing an organic sulfonic acid salt compound of SM-108. Further, a crystalline SM-108 compound containing a trace amount of an organic carboxylic acid can be produced by using an aqueous solution of the organic sulfonic acid salt of SM-108, and by adding an alkali metal salt of an organic carboxylic acid to the aqueous solution to neutralize the aqueous solution and then causing the crystal precipitation in the solution.
IMIDAZOPYRAZINE COMPOUNDS
-
Page/Page column 69, (2009/04/25)
Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.
SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
-
Page/Page column 185, (2008/06/13)
This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

